Saniona’s new CBO on strategy and business development

Saniona has recruited Wendy Dwyer to the position of Chief Business Officer. BioStock reached out to Dwyer, who played a key role in securing an 815...
Pila Pharma takes final steps before toxicology studies

Pila Pharma takes final steps before toxicology studies

After this summer's IPO, Malmö-based Pila Pharma is at full activity, preparing for the upcoming phase IIb study with drug candidate XEN-D0501. In its...
Cereno Scientific IND acceptance

Cereno Scientific receives IND acceptance for phase II start

The FDA has accepted Cereno Scientific’s Investigational New Drug application for the company’s lead drug candidate CS1. This allows Cereno to start the planned...
Completed recruitment in RhoVac's phase IIb trial

Completed recruitment in RhoVac’s phase IIb trial

The covid-19 pandemic came as an unwelcome guest for many drug developers around the world, resulting in delayed and discontinued studies. Lund-based RhoVac is...

PolarCool signs agreements with top Swedish hockey leagues

Polarcool’s cooling method for treating concussions keeps gaining acceptance across professional sports in the Nordics. Recently, the company renewed their contract with the Swedish...
Abliva's NV354 to progress to clinical development

Abliva’s NV354 to progress to clinical development

Biopharma company Abliva ended last week on a high note when it announced positive feedback from the MHRA, the UK regulatory authority, regarding its...

Coegin Pharma on the cusp of initiating COAK Study

Nordic biotech Coegin Pharma reached a key milestone this summer by receiving the green light from the Danish Medicines Agency to begin the Copenhagen Actinic...

Gabather poised to complete phase I with GT-002

As described in their Q2 report, despite the pandemic, Swedish biotech Gabather have taken key steps in the clinical development of its lead candidate...
Invent Medic accelerates

Invent Medic to accelerate with rights issue

The Lund-based tech company Invent Medic is currently in an intensive phase in its transition towards becoming a more sales-focused company, and in the...

BioStock Studio: Immunicum’s CEO on the company’s new therapeutic focus

Swedish immunotherapy company Immunicum has broadened its cancer treatment focus with the addition of drug candidate DCP-001 thanks to the merger with Dutch biotech...